Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 02 2022 - 8:00AM
Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”),
a biopharmaceutical company focused on modality-agnostic targeted
oncology for patients with cancer, today announced that David P.
Ryan, M.D. has been appointed to the company’s Board of Directors
(“Board”). Dr. Ryan brings over 20 years of oncology experience and
joins Cullinan Oncology from Massachusetts General Hospital (“MGH”)
Cancer Center where he holds the position of Clinical Director and
has been the Chief of the MGH Cancer Center since 2012.
Dr. Ryan holds a doctoral degree in medicine from Columbia
College of Physicians and Surgeons. Following the completion of his
doctoral program, Dr. Ryan began his career at
Columbia-Presbyterian Medical Center as an intern in Internal
Medicine and became chief resident in the Internal Medicine
department during his postdoctoral training. In 1998 Dr. Ryan
joined MGH, where he has held positions of increasing
responsibility over the last two decades, specializing in the
research and treatment of patients with cancer. Along with his
professional experience, Dr. Ryan has held many academic posts,
including his current position of Shelby Memorial Professor of
Medicine in the Field of Cancer Therapeutics at Harvard Medical
School. The principal focus of Dr. Ryan’s clinical research is the
design and implementation of clinical trials in gastrointestinal
malignancies.
In addition to his professional, academic, and leadership roles,
Dr. Ryan devotes much of his time to numerous medical and hospital
associations and committees, including as a member of the American
Society for Clinical Oncology. Dr. Ryan also currently serves as an
Advisor to both MPM and BioImpact Capital, an affiliate manager of
MPM.
Dr. Ryan will be replacing Ansbert Gadicke, M.D. on the Board of
Cullinan Oncology. Dr. Gadicke has served as the founder, lead
investor, and initial Chairman of the Cullinan Oncology Board since
its inception in September of 2016. He is the Managing Partner
of BioImpact Capital, the investment manager of the Oncology Impact
Funds, and a Managing Director at its affiliate MPM Capital.
“I am pleased to welcome Dr. David Ryan to the Cullinan Oncology
Board of Directors, where his expertise in oncology clinical
research will be invaluable to the company as Cullinan Oncology
advances its diverse pipeline through clinical development,” said
Tony Rosenberg, Chairman of the Board of Cullinan Oncology. “Dr.
Ryan brings with him years of experience in oncology and a proven
record of leadership in clinical research across hematologic
cancers and solid tumors. At the same time, I thank Dr. Ansbert
Gadicke for his years of service on the Cullinan Oncology Board of
Directors. Dr. Gadicke was a founding member of the organization
and helped shepherd it from a private to public company. His
strategic guidance throughout the process was invaluable to the
organization. The Board of Directors and leadership team benefited
greatly from his significant contributions over the years, and we
thank him for his service. We look forward to Dr. Ryan continuing
our important work as the company works towards it mission to
create new standards of care for patients with cancer.”
About Cullinan OncologyCullinan Oncology, Inc.
(NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating
new standards of care for patients with cancer. We innovate without
borders to find the most promising clinic-ready cancer therapies,
whether from our own discovery efforts or through exceptional
engagement with our academic and industry partners. Anchored in a
deep understanding of immuno-oncology and translational cancer
medicine, we leverage our scientific excellence in small molecules
and biologics to create differentiated ideas, identify unique
targets, and select the optimal modality to develop transformative
therapeutics across cancer indications. Powered by our novel
research model, we push conventional boundaries from candidate
selection to cancer therapeutic, applying rigorous early
experimentation to fast-track only the most promising assets to the
clinic and ultimately commercialization. As a result, our
diversified pipeline is strategically built with assets that
activate the immune system or inhibit key oncogenic drivers across
a wide range of modalities, each with the potential to be the best
or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024